# Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

> **NCT04269200** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 805 (actual)

## Conditions studied

- Endometrial Neoplasms

## Interventions

- **DRUG:** olaparib
- **BIOLOGICAL:** durvalumab
- **DRUG:** durvalumab placebo
- **DRUG:** olaparib placebo
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04269200
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-05
- **Primary completion:** 2024-07-08
- **Final completion:** 2027-04-01
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269200, "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04269200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*